

VU Research Portal

Circulating endothelial and progenitor cells during anti-angiogenic treatment in cancer patients

Vroling, L.

2011

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Vroling, L. (2011). *Circulating endothelial and progenitor cells during anti-angiogenic treatment in cancer patients*.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

CURRICULUM VITAE AND PUBLICATIONS

CURRICULUM VITAE

Laura Vroling werd geboren op 2 maart 1980 te Hoorn. In 1997 behaalde ze haar HAVO diploma aan de 'RSG' te Enkhuizen. In 1997 startte zij met de studie medische beeldvormende en radiotherapeutische technieken aan de Hogeschool van Haarlem. In 2001 studeerde zij af, waarna zij begon aan haar 3-jarige verkorte studie Biomedische Wetenschappen aan de Vrije Universiteit te Amsterdam. Tijdens deze studie heeft zij onderzoek uitgevoerd op de afdeling Kinderoncologie van het VU Medisch Centrum onder begeleiding van Dr. Jacqueline Cloos. Voor deze stage heeft zij drie maanden onderzoek verricht in het ziekenhuis van de Gadjah Mada Universiteit te Yogyakarta, Indonesie. Hier onderzocht zij polymorfismen in acute lymfoblastische leukemie bij Indonesische kinderen. Dit onderzoek werd voortgezet op de afdeling kinderoncologie van het VU medisch centrum. Het doctoraal diploma werd behaald in 2004. Vervolgens begon zij aan haar promotieonderzoek binnen de afdeling Medische Oncologie van het VU Medisch Centrum onder begeleiding van Prof.dr. Victor van Hinsbergh, Prof. Dr. Henk Verheul en Dr. Henk Broxterman. Het promotie onderzoek dat verricht is staat beschreven in dit proefschrift getiteld: "Circulating endothelial and progenitor cells during anti-angiogenic treatment in cancer patients". Na haar promotieonderzoek is zij nog betrokken geweest bij klinisch onderzoek en heeft additionele bloed-analyses gerelateerd aan het onderzoek beschreven in dit proefschrift. Momenteel is zij werkzaam als Clinical Research Manager.

CURRICULUM VITAE

Laura Vroling was born at March 2nd 1980 in Hoorn, The Netherlands. In 1997 she obtained her HAVO diploma at the 'RSGI in Enkhuizen. Afterwards, she started the education HBO-MBRT (Medical Imaging and Radiotherapeutic Techniques) at the Hogeschool Haarlem, in Haarlem. In 2001 she graduated, after which she started the 3-years reduced training Biomedical Sciences at the VU University in Amsterdam. During this study she performed an internship at the department of Paediatric Oncology, at the VU University Medical Center in Amsterdam under supervision of Dr. Jacqueline Cloos. For the duration of three months she performed research in the Gadjah Mada University in Yogyakarta, Indonesia. Here she examined polymorphisms in acute lymphoblastic leukemia in Indonesian children. This research was continued at the pediatric oncology department of the VU University Medical Center. The doctoral degree was obtained in 2004. Then she started her doctoral research within the Department of Medical Oncology at the VU University Medical Center under the supervision of Prof. Victor van Hinsbergh, Prof. Dr. Henk Verheul and Dr. Henk Broxterman. The doctoral research is described in this dissertation entitled "Circulating endothelial and progenitor cells during anti-angiogenic treatment in cancer patients". After her thesis- research she has been working on additional blood analyses related to the research described in this thesis. Currently she is working as a Clinical Research Manager.

LIST OF PUBLICATIONS

- **Vroling L.**, Koolwijk P., de Haas R.R., van Wijhe M., Verheul H. M.W., Broxterman H. J., van Hinsbergh V.W.M. Outgrowth arrest of circulating endothelial colony forming cells by hypoxia. *[To be submitted]*
- **Vroling, L.**, Lind J.S.W., de Haas R.R., Verheul H.M.W., van Hinsbergh V.W.M, Broxterman H.J., Smit E.F. CD133⁺ circulating hematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. *Br J Cancer* 2010 Jan 19; 102(2):268-75.
- Bijnsdorp I.V., Vrijland K., **L. Vroling**, Fukushima M., Peters G.J. Increased migration by stimulation of thymidine phosphorylase in endothelial cells of different origin. *Nucleosides Nucleotides Nucleic Acids*. 2010 Jun;29(4-6):482-7.
- **Vroling L.**, van der Veldt A.A., de Haas R.R., Haanen J.B.A.G., Schuurhuis G.J., Kuik D.J., van Crujisen H., Verheul H.M.W., van den Eertwegh A.J., Hoekman K., Boven E., van Hinsbergh V.W.M., Broxterman H.J. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. *Angiogenesis*. 2009;12(1):69-79.
- van der Veldt A.A, Boven E., **Vroling L.**, Broxterman H.J., van den Eertwegh A.J., Haanen J.B.A.G. Sunitinib-induced hemoglobin changes are related to the dosing schedule. *J Clin Oncol*. 2009 Mar 10;27(8):1339-40.
- van Crujisen H., van der Veldt A.A., **Vroling L.**, Oosterhoff D., Broxterman H.J., Scheper R.J., Giaccone G., Haanen J.B.A.G., van den Eertwegh A.J., Boven E., Hoekman K., de Gruijl T.D. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c⁺ dendritic cell frequency predicts progression-free survival. *Clin Cancer Res*. 2008 Sep 15;14(18):5884-92.
- **Vroling L.**, Yuana Y., Schuurhuis G.J., van Hinsbergh V.W.M., Gundy C., de Haas R.R., van Crujisen H., Boven E., Hoekman K., Broxterman H.J. VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients. *Thromb Haemost*. 2007 Aug;98(2):440-50.
- Giovannetti E., Ugrasena D.G., Supriyadi E., **Vroling L.**, Azzarello A., de Lange D., Peters G.J., Veerman A.J., Cloos J. Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia. *Leuk Res*. 2008 Jan;32(1):19-24.
